TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02271542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
Study: NCT00704080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
Study: NCT02328469

Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline

Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
Study: NCT02271542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
Study: NCT03142750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastrostomy tube dressing
Description: Two types of dressings to secure gastrostomy tube in children
Study: NCT02911467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate (13C)
Description: Pyruvate injection followed by an MRI scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan following the Pyruvate injection
Study: NCT01870570

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product A: Corn Flakes
Study: NCT03676764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
Study: NCT03040648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSA
Description: DSA was used for detection of intravascular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RTF
Description: RTF was used for detection of intravascular injection
Study: NCT01068821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel pad
Description: A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg crate foam mattress
Description: An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
Study: NCT03825328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: a combination preparation of tegafur, gimeracil, and oteracil potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
Study: NCT02414711

Intervention type: OTHER
Group type: OTHER
Intervention: HSCL25 scale
Description: The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)
Study: NCT01870570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product B: Ginger Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product C:Sandwiched Breakfast Biscuit
Study: NCT02414711

Intervention type: OTHER
Group type: OTHER
Intervention: HSCL25 scale
Description: The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)

Intervention type: OTHER
Group type: OTHER
Intervention: PSE9 questionary
Description: On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale

Intervention type: OTHER
Group type: OTHER
Intervention: PSE9 questionary
Description: On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
Study: NCT02505347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No splint
Description: Can move arm as tolerated with no restrictions on mobility
Study: NCT01870570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product D: Crackers Nature
Study: NCT02505347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Wear splint for 6 weeks, only to remove for rehab and personal care
Study: NCT05042245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ornithine aspartate granule simulant
Description: Ornithine aspartate granule simulant in the active comparator arm.
Study: NCT03138564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT
Description: SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Condition
Description: As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
Study: NCT02279316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vi-De 3
Description: All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vi-De 3
Description: All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.

Intervention type: DRUG
Group type: OTHER
Intervention: Vi-De 3
Description: All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze eurhythmics
Description: The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: The home exercise program is a strengthening program that will consist of five simple exercises.
Study: NCT04491279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home 'General' exercise instructions.
Description: Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home 'Neuropilates' exercise instructions.
Description: Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Neuropilates Group Class
Description: Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supervised General Exercises Group Class
Description: Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
Study: NCT03013595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAM feedback
Study: NCT02677584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic caffeine citrate
Description: Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic caffeine citrate
Description: Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
Study: NCT03443024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Sterile liquid solution administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Sterile liquid solution administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Sterile liquid solution administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution administered subcutaneously.
Study: NCT01870570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product E: Breakfast Biscuit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product F: White Bread
Study: NCT03443024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution administered subcutaneously.
Study: NCT02509338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)
Description: Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
Study: NCT03964662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeReha
Description: Rehabilitation of stroke patients with the device WeReha
Study: NCT00693459

Intervention type: DEVICE
Group type: OTHER
Intervention: Circular Anal Dilator for Transanal Hemorrhoidectomy
Description: The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
Study: NCT02346370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT01911325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buparlisib matching placebo
Study: NCT04487158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small Changes
Description: The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
Study: NCT01911325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT02287025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPAD application
Description: Investigators were supported with enhanced drug-specific information via an iPad application (SMART).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bayer specialist
Description: The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
Study: NCT03368430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
Study: NCT04487158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INSPIRE
Description: The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
Study: NCT03298880

Intervention type: DEVICE
Group type: OTHER
Intervention: Supine VM VAD
Description: Valsalva strain delivered using VAD
Study: NCT00782249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation paradigm #1
Description: Vagus nerve stimulation parameters #1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation paradigm #2
Description: Vagus nerve stimulation parameters #2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation paradigm #3
Description: Vagus nerve stimulation parameters #3
Study: NCT04184908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel xerostomia
Description: Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel placebo
Description: Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
Study: NCT03298880

Intervention type: DEVICE
Group type: OTHER
Intervention: Supine VAD manometer
Description: supine Valsalva strain delivered using manometer

Intervention type: OTHER
Group type: OTHER
Intervention: Modified VM VAD
Description: modified VM using VAD

Intervention type: OTHER
Group type: OTHER
Intervention: Modified VM Manonmeter
Description: Postural modified position VM using manometer
Study: NCT03804749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin sodium
Description: The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin sodium
Description: The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin sodium
Description: The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Study: NCT02328469

Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
Study: NCT03804749

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is 0.9% sodium chloride injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is 0.9% sodium chloride injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is 0.9% sodium chloride injection.
Study: NCT04196907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse CO-Oximeter and DCI Mini sensor
Description: Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
Study: NCT00829764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: 25 mg 5 mL dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Monohydrate
Description: 25 mg 5 mL dose
Study: NCT04336228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20mg daily for 3-4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20mg daily for 3-4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 20mg placebo tablet daily for 3-4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 20mg placebo tablet daily for 3-4 weeks.